Related Experiment Videos
Adriamycin and mitomycin C: possible synergistic cardiotoxicity
Cancer Treatment Reports
|July 1, 1978
Summary
Mitomycin C (MMC) combination chemotherapy in advanced breast cancer patients showed a higher incidence of congestive heart failure (CHF). Late-onset CHF suggests MMC may be a cardiotoxic agent, requiring careful patient monitoring.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
Background:
- Advanced breast cancer often requires combination chemotherapy.
- Adriamycin (ADR)-containing regimens are standard but can have side effects.
- Alternative or additive agents are explored for treatment-resistant cases.
Purpose of the Study:
- To evaluate the efficacy and safety of mitomycin C (MMC) combined with megestrol acetate in advanced breast cancer patients.
- To assess the cardiotoxicity of MMC when added to ADR-containing chemotherapy.
Main Methods:
- A cohort of 91 patients with advanced breast cancer received MMC and megestrol acetate.
- A comparison group of 89 patients received ADR-containing chemotherapy without MMC.
- Incidence and timing of congestive heart failure (CHF) were recorded and compared.
Main Results:
- Congestive heart failure (CHF) occurred in 15.3% of MMC-treated patients versus 3.4% in the non-MMC group (P = 0.01).
- The median time to CHF onset was significantly longer in the MMC group (8.5 months) compared to the control group (1.5 months).
Conclusions:
- Mitomycin C (MMC) may be associated with a higher incidence of congestive heart failure (CHF) in advanced breast cancer patients.
- The significantly later onset of CHF in the MMC group suggests a potential cardiotoxic role for this agent.